FDA Approves New Imaging Agent for Alzheimer's Disease Diagnosis

The U.S. FDA has approved TAUKLARIFY (florquinitau F 18 injection), a tau PET imaging agent. This new diagnostic tool is intended to identify tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer's disease, offering potential for earlier and more precise detection.